Dawn  Rogers net worth and biography

Dawn Rogers Biography and Net Worth

EVP of Pfizer
Dawn Rogers joined American Securities in 2021. She focuses on all aspects of human capital leadership and organizational design across the firm’s portfolio companies.

Prior to joining American Securities, Dawn was EVP and Chief Human Resources Officer at Pfizer. Her career with Pfizer spanned more than twenty years across their global business working as a key member of the executive team supporting growth and innovation of the organization. Previously, she was Senior Director of Human Resources at Kos Pharmaceuticals, where she established the human resources function and built their commercial organization in preparation for their first product launch and IPO. Prior to joining Kos Pharmaceuticals, Dawn held human resources positions at Earth Tech Inc. and The Ares Serono Group/Serono Diagnostics.

Dawn received a BA in Psychology/Human Resources from Moravian College and an MS in Management from Lesley University.

What is Dawn Rogers' net worth?

The estimated net worth of Dawn Rogers is at least $797,035.50 as of March 4th, 2019. Ms. Rogers owns 28,722 shares of Pfizer stock worth more than $797,036 as of March 28th. This net worth approximation does not reflect any other assets that Ms. Rogers may own. Learn More about Dawn Rogers' net worth.

How do I contact Dawn Rogers?

The corporate mailing address for Ms. Rogers and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323. Learn More on Dawn Rogers' contact information.

Has Dawn Rogers been buying or selling shares of Pfizer?

Dawn Rogers has not been actively trading shares of Pfizer in the last ninety days. Most recently, Dawn Rogers sold 15,002 shares of the business's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $42.98, for a transaction totalling $644,785.96. Following the completion of the sale, the executive vice president now directly owns 28,722 shares of the company's stock, valued at $1,234,471.56. Learn More on Dawn Rogers' trading history.

Who are Pfizer's active insiders?

Pfizer's insider roster includes Ronald Blaylock (Director), Albert Bourla (DVM), Loretta Cangialosi (VP), William Carapezzi, Jr. (EVP), Albert D.V.M. (DVM), Frank Damelio (EVP), Frank D'Amelio (CFO & Exec. VP ), Jennifer Damico (SVP), Jennifer Damico (SVP), Scott Gottlieb (Director), Rady Johnson (Insider), Douglas Lankler (EVP), Alexander Mackenzie (EVP), Laurie Olson (Insider), Ian Read (CEO), Dawn Rogers (EVP), Sally Susman (Insider), and John Young (Insider). Learn More on Pfizer's active insiders.

Are insiders buying or selling shares of Pfizer?

In the last year, Pfizer insiders bought shares 3 times. They purchased a total of 5,000 shares worth more than $156,410.00. The most recent insider tranaction occured on December, 15th when Director Scott Gottlieb bought 3,000 shares worth more than $79,410.00. Insiders at Pfizer own 0.1% of the company. Learn More about insider trades at Pfizer.

Information on this page was last updated on 12/15/2023.

Dawn Rogers Insider Trading History at Pfizer

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/4/2019Sell15,002$42.98$644,785.9628,722View SEC Filing Icon  
See Full Table

Dawn Rogers Buying and Selling Activity at Pfizer

This chart shows Dawn Rogers's buying and selling at Pfizer by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pfizer Company Overview

Pfizer logo
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Read More

Today's Range

Now: $27.75
Low: $27.72
High: $28.12

50 Day Range

MA: $27.46
Low: $25.89
High: $28.43

2 Week Range

Now: $27.75
Low: $25.61
High: $42.22

Volume

39,620,254 shs

Average Volume

43,835,094 shs

Market Capitalization

$157.14 billion

P/E Ratio

77.08

Dividend Yield

6.09%

Beta

0.61